Dr Gregory C Critchfield, MD | |
6170 Murdoch Woods Pl, Holladay, UT 84121-2206 | |
(801) 541-2322 | |
Not Available |
Full Name | Dr Gregory C Critchfield |
---|---|
Gender | Male |
Speciality | Pathology - Clinical Pathology |
Location | 6170 Murdoch Woods Pl, Holladay, Utah |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1801101373 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207ZC0006X | Pathology - Clinical Pathology | 176973-1205 (Utah) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Gregory C Critchfield, MD 6170 Murdoch Woods Pl, Holladay, UT 84121-2206 Ph: (801) 541-2322 | Dr Gregory C Critchfield, MD 6170 Murdoch Woods Pl, Holladay, UT 84121-2206 Ph: (801) 541-2322 |
News Archive
Workaholics work hard, but still have poor job performance—mainly because of high mental and physical strain, according to a study in the November Journal of Occupational and Environmental Medicine, official publication of the American College of Occupational and Environmental Medicine.
The Los Angeles Times reports on a Democratic plan to cancel scheduled cuts to physician pay under the Medicare program with a bill separate from their sweeping health reform proposal. It would allow lawmakers to "reconcile a nearly $250-billion difference between the House and Senate" while at the same time keeping the American Medical Association on board with their plans.
Until today, the proteins known as ubiquitin receptors have been associated mainly with protein degradation, a basic cell cleaning process. A new function now described for the protein dDsk2 by the team headed by Ferran AzorĂn, group leader at the Institute for Research in Biomedicine (IRB Barcelona) and CSIC research professor, links ubiquitin receptors for the first time with the regulation of gene expression.
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced the publication of a research article in Bioorganic & Medicinal Chemistry Letters on the anti-tumor activity of RX-8243 and its analogues.
› Verified 7 days ago